<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04296162</url>
  </required_header>
  <id_info>
    <org_study_id>1503144-7</org_study_id>
    <nct_id>NCT04296162</nct_id>
  </id_info>
  <brief_title>Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)</brief_title>
  <acronym>ORCHID</acronym>
  <official_title>A Phase II Study to Assess the Effectiveness and Safety of Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open-lable Phase II clinical trial (ORCHID study) evaluating the
      effectiveness and safety of oral vinorelbine or capecitabine combined with trastuzumab as
      adjuvant treatment for patients with lymph node negative, HER-2 positive and small tumor size
      breast cancer
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">May 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease free survival</measure>
    <time_frame>5 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>distant disease free survival</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">178</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 cycle of oral vinorelbine or capecitabine combined with trastuzumab (21 days per cycle), followed by sequential single trastuzumab to 1 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>Vinorelbine chemotherapy (oral)</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine chemotherapy (oral)</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Trastuzumab target therapy</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. women aged 18-70 years old;

          2. T ≤1cm and negative lymph node confirmed by histopathology after early breast cancer
             surgery

          3. HER2 positive confirmed by histopathology after early breast cancer
             surgery（HER2-positive breast cancer defined as a positive in situ hybridization test
             or an Immunohistochemistry (IHC) status of 3+. If IHC is 2+, a negative in situ
             hybridization (Fluorescence in situ hybridization (FISH), Chromogenic in situ
             hybridization (CISH) , or Silver in situ hybridization (SISH)) test is required by
             local laboratory testing.)

          4. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

          5. Has adequate organ function meeting the following criteria: (1) adequate bone marrow
             function: hemoglobin ≥ 90 g/L (no blood transfusion within 14 days); absolute
             neutrophil count ≥ 1.5 x 109 /L; platelet count ≥ 100 * 109 /L; (2)adequate liver and
             kidney function: Alanine Aminotransferase (ALT) ≤ 3×upper limit of normal (ULN),
             Aspartate Aminotransferase (AST) ≤ 3×ULN, Total Bilirubin (TBIL)≤ 1.5×ULN, serum
             creatinine ≤ 1×ULN，and with endogenous creatinine clearance rate of &gt;50 ml/min
             (Cockcroft-Gault formula).

          6. Participants voluntarily joined the study, has signed informed consent before any
             trial related activities are conducted, has good compliance and has agreed to
             follow-up.

        Exclusion Criteria:

          1. Has received neoadjuvant therapy (include chemotherapy, targeted therapy, radiotherapy
             or endocrine therapy）;

          2. Has bilateral breast cancer;

          3. Has previous history of additional malignancy, with the exception of adequately
             treated basal cell carcinoma and cervical carcinoma in situ.

          4. Has metastic (Stage 4) breast cancer;

          5. Is pregnant, is breast feeding women, or women of childbearing age who cannot practice
             effective contraceptives;

          6. Patients participating in other clinical trials at the same time;

          7. Has severe organ dysfunction (cardiopulmonary liver and kidney) insufficiency, left
             ventricular ejection fraction (LVEF) &lt; 50% (cardiac ultrasound); severe cardio
             cerebral vascular disease within the 6 months previous of randomization (such as
             unstable angina, chronic heart failure, uncontrolled hypertension with blood
             pressure&gt;150/90mmgh, myocardial infarction, or cerebral blood vessel); diabetic
             patients with poor blood glucose control; patients with severe hypertension;

          8. Has severe or uncontrolled infection;

          9. Has a history of psychotropic substance abuse and were unable to abandon drug habits,
             or those with history of mental disorders;

         10. the researchers judged patients to be unsuitable for the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhi-Ming Shao</last_name>
    <phone>86-021-64175590</phone>
    <phone_ext>8808</phone_ext>
    <email>zhiimingshao@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhi-Ming Shao</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhi-Ming Shao</last_name>
      <email>zhimingshao@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 3, 2020</study_first_submitted>
  <study_first_submitted_qc>March 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2020</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhimin Shao</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>oral vinorelbine</keyword>
  <keyword>capecitabine</keyword>
  <keyword>trastuzumab</keyword>
  <keyword>adjuvant treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

